Cargando…

Immune response to SARS-CoV-2 in severe disease and long COVID-19

COVID-19 is mild to moderate in otherwise healthy individuals but may nonetheless cause life-threatening disease and/or a wide range of persistent symptoms. The general determinant of disease severity is age mainly because the immune response declines in aging patients. Here, we developed a mathemat...

Descripción completa

Detalles Bibliográficos
Autores principales: Sumi, Tomonari, Harada, Kouji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9251893/
https://www.ncbi.nlm.nih.gov/pubmed/35813874
http://dx.doi.org/10.1016/j.isci.2022.104723
_version_ 1784740133436653568
author Sumi, Tomonari
Harada, Kouji
author_facet Sumi, Tomonari
Harada, Kouji
author_sort Sumi, Tomonari
collection PubMed
description COVID-19 is mild to moderate in otherwise healthy individuals but may nonetheless cause life-threatening disease and/or a wide range of persistent symptoms. The general determinant of disease severity is age mainly because the immune response declines in aging patients. Here, we developed a mathematical model of the immune response to SARS-CoV-2 and revealed that typical age-related risk factors such as only a several 10% decrease in innate immune cell activity and inhibition of type-I interferon signaling by autoantibodies drastically increased the viral load. It was reported that the numbers of certain dendritic cell subsets remained less than half those in healthy donors even seven months after infection. Hence, the inflammatory response was ongoing. Our model predicted the persistent DC reduction and showed that certain patients with severe and even mild symptoms could not effectively eliminate the virus and could potentially develop long COVID.
format Online
Article
Text
id pubmed-9251893
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-92518932022-07-05 Immune response to SARS-CoV-2 in severe disease and long COVID-19 Sumi, Tomonari Harada, Kouji iScience Article COVID-19 is mild to moderate in otherwise healthy individuals but may nonetheless cause life-threatening disease and/or a wide range of persistent symptoms. The general determinant of disease severity is age mainly because the immune response declines in aging patients. Here, we developed a mathematical model of the immune response to SARS-CoV-2 and revealed that typical age-related risk factors such as only a several 10% decrease in innate immune cell activity and inhibition of type-I interferon signaling by autoantibodies drastically increased the viral load. It was reported that the numbers of certain dendritic cell subsets remained less than half those in healthy donors even seven months after infection. Hence, the inflammatory response was ongoing. Our model predicted the persistent DC reduction and showed that certain patients with severe and even mild symptoms could not effectively eliminate the virus and could potentially develop long COVID. Elsevier 2022-07-04 /pmc/articles/PMC9251893/ /pubmed/35813874 http://dx.doi.org/10.1016/j.isci.2022.104723 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Sumi, Tomonari
Harada, Kouji
Immune response to SARS-CoV-2 in severe disease and long COVID-19
title Immune response to SARS-CoV-2 in severe disease and long COVID-19
title_full Immune response to SARS-CoV-2 in severe disease and long COVID-19
title_fullStr Immune response to SARS-CoV-2 in severe disease and long COVID-19
title_full_unstemmed Immune response to SARS-CoV-2 in severe disease and long COVID-19
title_short Immune response to SARS-CoV-2 in severe disease and long COVID-19
title_sort immune response to sars-cov-2 in severe disease and long covid-19
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9251893/
https://www.ncbi.nlm.nih.gov/pubmed/35813874
http://dx.doi.org/10.1016/j.isci.2022.104723
work_keys_str_mv AT sumitomonari immuneresponsetosarscov2inseverediseaseandlongcovid19
AT haradakouji immuneresponsetosarscov2inseverediseaseandlongcovid19